Buccal Drug Delivery Systems Market by Type (Buccal Tablets, Oral Sprays, Sublingual Films), Application (Angina Pectoris, Pain Management, Smoking Cessation), End-user - Global Forecast 2023-2030

Buccal Drug Delivery Systems Market by Type (Buccal Tablets, Oral Sprays, Sublingual Films), Application (Angina Pectoris, Pain Management, Smoking Cessation), End-user - Global Forecast 2023-2030


The Buccal Drug Delivery Systems Market is projected to reach USD 4.18 billion by 2030 from USD 2.05 billion in 2022, at a CAGR of 9.27% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Buccal Drug Delivery Systems Market.
  • Based on Type, market is studied across Buccal Tablets, Oral Sprays, and Sublingual Films. The Sublingual Films is projected to witness significant market share during forecast period.
  • Based on Application, market is studied across Angina Pectoris, Pain Management, and Smoking Cessation. The Pain Management is projected to witness significant market share during forecast period.
  • Based on End-user, market is studied across Ambulatory Centers and Hospitals. The Ambulatory Centers is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Buccal Drug Delivery Systems Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Buccal Drug Delivery Systems Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Buccal Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Amgen Inc., Aquestive Therapeutics, Inc., ARx, LLC, AstraZeneca Plc, Camurus, Catalent, Inc., Cure Pharmaceutical, DuPont de Nemours, Inc., Generex Biotechnology, Herantis Pharma PLC, Indivior PLC, LTS Lohmann Therapie-Systeme AG, MedLab Clinical Ltd, Nektar Therapeutics, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sorrento Therapeutics, Inc., Tesa Labtec GmbH, and Vectura Group.

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Buccal Drug Delivery Systems Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Buccal Drug Delivery Systems Market?
  3. What is the competitive strategic window for identifying opportunities in the Buccal Drug Delivery Systems Market?
  4. What are the latest technology trends and regulatory frameworks in the Buccal Drug Delivery Systems Market?
  5. What is the market share of the leading vendors in the Buccal Drug Delivery Systems Market?
  6. Which modes and strategic moves are suitable for entering the Buccal Drug Delivery Systems Market?


Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Buccal Drug Delivery Systems Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High preferences due to ease of drug administration and termination
5.1.1.2. Prevalence of chronic diseases coupled with growth in geriatric population
5.1.1.3. Increased demand for drug development globally
5.1.2. Restraints
5.1.2.1. Difficulty in administration of large doses
5.1.3. Opportunities
5.1.3.1. Advances in nanoparticulate drug delivery approaches for buccal administration
5.1.3.2. Developments in buccal mucoadhesive tablets
5.1.4. Challenges
5.1.4.1. Issues with patient acceptability for non ubiquitous drug distribution within saliva
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Buccal Drug Delivery Systems Market, by Type
6.1. Introduction
6.2. Buccal Tablets
6.3. Oral Sprays
6.4. Sublingual Films
7. Buccal Drug Delivery Systems Market, by Application
7.1. Introduction
7.2. Angina Pectoris
7.3. Pain Management
7.4. Smoking Cessation
8. Buccal Drug Delivery Systems Market, by End-user
8.1. Introduction
8.2. Ambulatory Centers
8.3. Hospitals
9. Americas Buccal Drug Delivery Systems Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Buccal Drug Delivery Systems Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Buccal Drug Delivery Systems Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. 3M Company
13.1.2. Amgen Inc.
13.1.3. Aquestive Therapeutics, Inc.
13.1.4. ARx, LLC
13.1.5. AstraZeneca Plc
13.1.6. Camurus
13.1.7. Catalent, Inc.
13.1.8. Cure Pharmaceutical
13.1.9. DuPont de Nemours, Inc.
13.1.10. Generex Biotechnology
13.1.11. Herantis Pharma PLC
13.1.12. Indivior PLC
13.1.13. LTS Lohmann Therapie-Systeme AG
13.1.14. MedLab Clinical Ltd
13.1.15. Nektar Therapeutics
13.1.16. Novartis AG
13.1.17. Novo Nordisk A/S
13.1.18. Pfizer Inc.
13.1.19. Sorrento Therapeutics, Inc.
13.1.20. Tesa Labtec GmbH
13.1.21. Vectura Group
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings